Securities Code: 300685 Securities Abbreviation: Ad Biomedicine Announcement No.: 2026-011
Xiamen Ad Biomedicine R&D Co., Ltd. Announcement of the Resolution of the 11th Meeting of the Fourth Board of Directors
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The 11th Meeting of the Fourth Board of Directors of Xiamen Ad Biomedicine R&D Co., Ltd. (hereinafter referred to as the "Company" or "Ad Biomedicine") was held on April 14, 2026, at the company's meeting room located at 39 Ding Shan Road, Haicang District, Xiamen City, through a combination of communication and on-site voting. A total of 7 directors were eligible to attend, and all 7 directors were present, which met the quorum requirement stipulated in the Company's Articles of Association. Company supervisors and senior management personnel attended the meeting. The meeting notice was sent out via email and other means on April 4, 2026. The notice and convening of the meeting complied with the provisions of the "Company Law" and the "Articles of Association." The meeting was presided over by Mr. LI-MOU ZHENG, Chairman of the Company.
II. Deliberation and Resolution of the Board Meeting
-
Approval of the "2025 Annual Report of the General Manager" Voting Results: 7 votes in favor, 0 votes against, 0 abstentions. This proposal was approved. The Board of Directors heard the "2025 Annual Report of the General Manager" made by the Company's General Manager. It was considered that in 2025, the Company's management diligently and effectively implemented all resolutions of the Shareholders' Meeting and the Board of Directors, actively carried out various tasks, and laid a solid foundation for long-term stable development. Detailed content can be found in the Company's 2025 Annual Report, which is published on the same day as this announcement on the information disclosure website designated by the China Securities Regulatory Commission for the ChiNext market.
-
Approval of the "2025 Annual Report of the Board of Directors" Voting Results: 7 votes in favor, 0 votes against, 0 abstentions. This proposal was approved. Detailed content can be found in the Company's 2025 Annual Report, which is published on the same day as this announcement on the information disclosure website designated by the China Securities Regulatory Commission for the ChiNext market. The independent directors of the Company submitted their 2025 annual performance reports to the Board of Directors (which are published on the same day as this announcement on the information disclosure website designated by the China Securities Regulatory Commission for the ChiNext market) and will present them at the Company's 2025 Shareholders' Meeting. This proposal still needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation.
-
Approval of the "2025 Annual Report and its Summary" Voting Results: 7 votes in favor, 0 votes against, 0 abstentions. This proposal was approved. The full text of the 2025 Annual Report and its summary can be found on the information disclosure website designated by the China Securities Regulatory Commission for the ChiNext market. The summary of the 2025 Annual Report was published in the "Securities Times" on April 16, 2026. This proposal has been reviewed and approved by the Company's Board of Directors' Audit Committee. This proposal still needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation.